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Hepatocellular carcinoma (HCC) is one of
the leading causes of cancer-related mortality
in the world. In Taiwan, it is the most com-
mon cause of cancer death among men (1).
Risk factors for HCC include chronic
hepatitis B virus (HBV) infection, hepatitis
C virus (HCV) infection, cigarette smoking,
and dietary exposure to aﬂatoxin B1 (AFB1).
AFB1 is a naturally occurring mycotoxin
derived from certain species of Aspergillus
fungi that contaminates various foods, par-
ticularly peanuts/groundnuts, corn/maize,
and oil seeds and nuts such as cottonseed,
almonds, and pistachios. AFB1 is a potent
liver carcinogen in animals (2,3) and has
been categorized as a group I human car-
cinogen by the International Agency for
Research on Cancer (4).
Human exposure to AFB1 and its biologi-
cal effects are highly variable and are influ-
enced by several factors. AFB1 production by
Aspergillus fungi is influenced by humidity
and temperature. Dietary exposure of AFB1 is
inﬂuenced by harvesting and storage condi-
tions of foods and procedures used for cook-
ing. In the body, AFB1 is metabolized by the
microsomal mixed-function enzymes, which
are inherently polymorphic, to various
reduced and oxidized derivatives, including
an unstable reactive AFB1-8, 9-epoxide,
which can bind covalently to DNA and pro-
teins. The biologically effective dose of AFB1
can be measured in urine as AFB1–guanine,
in liver tissues as AFB1–DNA, and in periph-
eral blood as AFB1–albumin adduct, but
AFB1–albumin adducts have been considered
the most reliable biomarker of AFB1 exposure
in humans (5). Because of a relatively long
half-life of serum albumin, the AFB1–albu-
min adduct reﬂects AFB1 exposure from the
past 2–3 months (5). AFB1–albumin adduct
has been shown to be related to HCC risk in
a dose–response fashion among HBV surface
antigen (HBsAg) carriers, and the biological
gradient was particularly pronounced among
subjects who carried null genotypes of glu-
tathione S-transferase (GST) M1 and/or T1
metabolism genes (6).
The temporal trend in the AFB1–albumin
adduct level was examined during two 12-
week monitoring periods within a year among
120 individuals in Qidong, China (7). The
study subjects, comprising roughly equal
numbers of males and females and HBsAg
carriers and noncarriers, were selected by
screening 600 healthy volunteers older than
18 years of age. The authors found continu-
ously detectable levels of AFB1–albumin
adducts among the study participants, with
an increasing trend in adduct levels during the
first wave (September–December) and a
somewhat decreasing trend during the second
wave (June–September). These trends were
not modiﬁed by gender or HBsAg status (7).
In the present study, we examined
AFB1–albumin adducts among a sample of
healthy adults in Taiwan over a period of
1–3 years and examined whether the AFB1
exposure as measured by AFB1–albumin
adduct levels and its temporal (or intraindi-
vidual) variability are modified by HBsAg,
anti-HCV, GSTM1 or GSTT1 genotype,
seasonal variation, and other factors.
Examination of temporal variability in
adduct levels is useful in evaluating whether
adduct levels indicate changes in the expo-
sure to aflatoxin in the population (e.g.,
monitoring effectiveness of intervention/pre-
vention trials). Understanding the roles of
host factors (i.e., HBsAg, anti-HCV, and
GST genotype status) on the variability in
adduct levels may help in identifying suscep-
tible populations for targeting speciﬁc public
health interventions.
Methods
Study subjects. The study subjects were a
sample drawn from a cancer screening pro-
ject cohort that was assembled during
1990–1992. Details of the recruitment meth-
ods and characteristics of this parent cohort
have been published previously (8). Brieﬂy,
25,618 (12,024 men and 13,594 women)
volunteer respondents 30–64 years of age
were recruited from seven urban and rural
townships in Taiwan (four townships on
Taiwan Island and three townships on the
Penghu Islets). These people responded to
the letter of invitation sent to residents in
the selected townships who were born
between 1927 and 1961. In addition to the
cancer screening, in-person interviews with a
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Exposure to aflatoxin B1 (AFB1), an important cofactor in the etiology of hepatocellular carci-
noma in Taiwan, is influenced by dietary and other factors. The present study examined the
intraindividual variability in AFB1–albumin adducts, the most reliable long-term biomarker of
AFB1 exposure, and whether the baseline or follow-up adduct levels and the intraindividual vari-
ability in adduct levels are modiﬁed by endogenous and environmental factors. The study mea-
sured AFB1–albumin adduct levels among 264 healthy male residents of three townships
(Hu-Hsi, Ma-Kung, and Pai-Hsa) of Penghu Islets, Taiwan, at two different time points with a
median interval of 1.68 years (range 1.00–3.17 years). There was a generalized reduction in the
adduct levels, with the median values being 22.1 pmol/mg (range 5.0–355.8 pmol/mg) at time 1
and 14.3 pmol/mg (range 5.0–205.2 pmol/mg) at time 2. This intraindividual variability in
adduct levels was inversely associated with the age of subjects and the time interval between the
two blood draws. The variability in adduct levels was lower among subjects in Hu-Hsi and Pai-
Hsa townships as compared to those in Ma-Kung. No signiﬁcant association was observed for the
intraindividual variability in AFB1–albumin adducts with regard to the season when blood was
drawn. There was also no signiﬁcant association between intraindividual variability and hepatitis
B surface antigen, anti-hepatitis C virus (anti-HCV), glutathione S-transferase (GST) M1, or
GSTT1 status. In conclusion, we found substantial intraindividual variability in the AFB1 expo-
sure (as determined by AFB1–albumin adducts) in Taiwan, which was probably more likely
related to dietary or other environmental influences rather than to endogenous factors (e.g.,
hepatitis B/C viral infection or GST M1/T1 genetic status). Key words: aflatoxin–albumin
adducts, biomarkers, intraindividual variability, liver cancer, molecular epidemiology. Environ
Health Perspect 109:833–837 (2001). [Online 13 August 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p833-837ahsan/abstract.htmlstructured questionnaire were conducted at
the local research centers with the partici-
pants at the time of recruitment. We col-
lected 20 mL of fasting blood (10 mL in a
heparinized tube and 10 mL in a tube with-
out anticoagulant) from each participant at
the time of recruitment; buffy coat, plasma,
and red blood cells were separated and stored
at the central laboratory of National Taiwan
University at –70°C. Subjects in this cohort
who were screened positive by serological
markers (i.e., high serum alanine transami-
nase, aspartate transaminase, or α -fetoprotein
levels) or had abnormal liver ultrasound pro-
vided blood samples every 6–12 months for
further clinical monitoring. The cohort
members who were apparently healthy and
had normal levels of serological markers and
ultrasound provided a repeat sample of blood
within 1–3 years as part of follow-up visits.
From these healthy members of the cohort,
we selected 264 apparently healthy men for
the current study for the examination of
intraindividual variability of AFB1–albumin
adducts. These 264 individuals were selected
randomly from the participating residents of
three townships (Hu-Hsi, Ma-Kung, and
Pai-Hsa) in Penghu Islets, an area with the
highest HCC incidence in Taiwan, but in a
manner so that half (n = 132) of them were
HBsAg carriers and the other half (n = 132)
were noncarriers.
Laboratory analysis. As mentioned
above, HBsAg and HCV assays were con-
ducted on all participants as part of the par-
ent cancer screening project cohort study at
National Taiwan University. HBsAg status
was tested by enzyme immunoassay using
commercial kits (Abbott Laboratories, North
Chicago, IL, USA). Antibodies against HCV
were also tested using an enzyme immunoas-
say with second-generation commercial kits
(HCV; Abbott).
The biological samples of the 264 sub-
jects selected for the current study were
shipped to Regina Santella’s laboratory at
Columbia University, New York, for further
analyses. At Columbia, GSTM1 and GSTT1
genotypes were determined by polymerase
chain reaction amplification of genomic
DNA with published primers using β -globin
as an internal control and gel electrophoresis
as described (9,10).
To determine the AFB1–albumin adduct
levels in serum samples, we used an enzyme-
linked immunosorbent assay (ELISA) as
described previously (6,11). An antiserum for
detection of AFB1–albumin adduct was gen-
erated by immunizing New Zealand white
rabbits with bovine γ -globulin (BGG) modi-
fied with AFB1 epoxide synthesized as
described (12). Antiserum (#7) was used in a
competitive ELISA. For the ELISA standard
curve, [3H]AFB1–human serum albumin was
digested with proteinase K as described below
for the human samples and adducts isolated
by Seppak C18 (Waters, Milford, MA, USA)
extraction. We determined adduct level from
the speciﬁc activity.
Albumin was prepared from plasma
essentially as described (13), and its concen-
tration was determined with bicinchoninic
acid (BCA Reagent, Pierce, IL, USA). For
the digestion, 2 mg albumin and 0.5 mg pro-
teinase K were incubated 15 hr at 37°C.
Adducts were isolated by the procedure as
described (14), dissolved in 0.5% mL phos-
phate-buffered saline containing 1% fetal calf
serum and 1 mmol/L phenylmethylsulpho-
nylﬂuoride to inhibit residual protease activ-
ity, and assayed by competitive ELISA. This
assay had 50% inhibition of antiserum bind-
ing at 10–20 fmol AFB1 adduct per well.
The limit of sensitivity (15% inhibition),
when assaying the equivalent of 200 µg albu-
min/well, was 0.01 fmol/µg. Samples with
less than 15% inhibition were given a value
of 0.005 fmol/µg. Samples were assayed by
duplicate analysis in duplicate wells. We ana-
lyzed two control samples with each batch of
sera: a pooled sample of plasma from non-
smoking American subjects and a positive
control of serum from a rat treated with 1.5
mg AFB1. Although samples were drawn at
different time points, all samples were
assayed at one time with the laboratory per-
sonnel being blinded to the time of blood
drawing and other individual information.
Statistical analysis. Median, mean, and
standard deviation (SD) of the adduct levels
were calculated for all 264 samples as well as
for the subgroups of samples separately for
the baseline and repeat samples. The adduct
levels between the two groups at a given time
point were compared by using t-tests or
Wilcoxon rank tests, depending on the distri-
bution of the data. To examine the temporal
variability of adduct levels among the same
subjects, the mean adduct levels between two
time points were compared using paired t-
tests. The effect of seasonal variability on the
adduct level was measured in two different
ways. First, to examine the effect of seasonal
variability on adduct level at any given time
point, the mean and median adduct levels
were examined for four different calendar
periods separately for time 1 (i.e., baseline
sample) and time 2 (i.e., follow-up sample).
Second, to examine the effect of season on
the temporal variability in adduct levels, sub-
jects who provided blood samples during the
same months in two different calendar years
were compared with subjects who provided
blood samples during different months in
two different calendar years. Because the
adduct levels were not normally distributed
(as evident from the differences between the
mean and median values presented in
Table 1), we used log-transformed values in
all multivariate analyses.
In multivariate analysis, to examine the
impact of different environmental and
genetic factors on adduct levels at a given
time point, linear regression models were ﬁt
using the adduct level as the outcome vari-
able separately for time 1 and time 2. To
examine the effect of different factors on the
temporal variability of adduct levels, a single
regression model was ﬁt using the differences
in the adduct levels between two time points
as the outcome variable. All regression mod-
els were rerun including a term for ELISA
batch in the model to adjust for the labora-
tory assay variability.
Results
AFB1–albumin adducts were measured in
264 subjects at two time points with a
median duration between the sample draws
of 1.68 years and a range of 1.00–3.17 years.
Table 1 shows the median (and also the
mean) adduct levels (picomoles of AFB1 per
milligram of albumin) at two time points for
all subjects as well as at different levels of
other characteristics. The median adduct
level for all subjects was 22.1 pmol/mg (range
5.0–355.8) at time 1 and 14.3 pmol/mg
(range 5.0–205.2) at time 2. Within each
time point, adduct levels were similar across
different categories of HBsAg, anti-HCV,
and GSTM1 and GSTT1 genotype status.
The effect of season on the adduct levels
appeared to be different for the two time
points. At time 1, adduct levels were higher
for subjects whose blood was drawn in
June–November, but at time 2, adduct levels
were lower for subjects whose blood was
drawn in June–November. At time 2, the
adduct levels were substantially lower among
the youngest age group as compared to other
age groups and also among subjects who had
a shorter time interval between the blood
draws as compared to those with a longer
time intervals.
Regarding the intraindividual variability
in adduct levels between two time points, the
median (and also the mean) adduct levels
were uniformly lower at the second time
point almost for all categories of different
environmental and endogenous factors. These
differences in adduct levels between the two
time points did not seem to vary by levels of
age, HBsAg and anti-HCV status, GSTM1
and GSTT1 genotype, and time interval or
seasonal variability between the blood draws.
The differences in the adduct levels between
two time periods, however, appeared to vary
with respect to geographic area, with Ma-
Kung having the highest variability.
Table 2 shows the results of multivariate
analyses examining the effects of different
variables on the adduct levels separately for
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vidual variability between two time points.
In both time periods, adduct levels seemed
to be signiﬁcantly positively associated with
age. Scattered plots of adduct levels against
age showed somewhat linear trends, espe-
cially for data in time 2 (data not shown). In
time 2, but not in time 1, adduct levels were
higher among subjects in Hu-Hsi and Pai-
Hsa as compared to those in Ma-Kung and
also higher among HBsAg carriers than
among noncarriers. The adduct levels were
also related to the seasonal variability in time
2 but not in time 1.
As shown in Table 2, the intraindividual
variability in adduct levels between two time
points was inversely associated with the age
of subjects and the time interval between the
two blood draws. The variability in adduct
levels was lower among subjects in Hu-Hsi
and Pai-Hsa as compared to those in Ma-
Kung. No significant association was
observed for the intraindividual variability in
AFB1–albumin adducts with regard to the
differences in season when blood was drawn.
There was also no significant association
between intraindividual variability and
HBsAg, anti-HCV, or GSTM1 or GSTT1
status. These results were similar when the
analysis was conducted excluding the 42
subjects whose GST genetic status could not
be determined.
Discussion
Although HBV infection is the key etiologic
element in HCC, AFB1 exposure is an
important cofactor in HCC carcinogenesis.
AFB1–albumin adduct is considered a reli-
able indicator of the biologically effective
dose of AFB1 exposure. In the present study
we examined how different environmental
and endogenous factors inﬂuence the effect
of AFB1 exposure as measured by the
AFB1–albumin adduct and also whether
these factors play roles in the temporal vari-
ability of adduct levels. To our knowledge,
only one previously published study has
examined the temporal variability in
AFB1–albumin adduct level among residents
of Qidong County, China, by examining
adduct levels at two different time periods
within a 1-year period (7).
In the present study we measured
AFB1–albumin adduct levels among 264
subjects at two time points with an interval
of 1–3 years among residents of three differ-
ent geographic areas in Taiwan. The adduct
levels observed in the current study are com-
parable to those observed in other studies in
Asia (7), but somewhat higher than those
reported in Africa (15). However, it is difﬁ-
cult to directly compare adduct levels across
studies because different detection methods
are used in different studies. The adduct lev-
els were on average substantially lower for the
second measure among all subjects, regardless
of their environmental or genetic characteris-
tics. This generalized reduction in adduct lev-
els was difﬁcult to explain. The study subjects
were apparently healthy residents who partic-
ipated in the cancer screening project.
Although specific interventions for dietary
modification were not done at the time of
recruitment (i.e., at time 1), the respondents
were briefed about the risk factors for HCC,
including hepatitis viruses and dietary afla-
toxin exposure. Therefore, one possibility is
that the participants modified their dietary
habits after participating in the cancer screen-
ing project. Although AFB1–albumin adduct
is considered to reflect exposure for a rela-
tively long period (up to 3 months), the time
intervals of blood draws for the study subjects
were sufﬁciently large (at least 1 year) for the
adduct measures to reﬂect dietary exposures
from non-overlapping time periods.
Both the baseline as well as the follow-up
measures of adduct levels were weakly but
somewhat positively correlated with age. The
temporal variability in the adduct levels was,
however, negatively correlated with age (i.e.,
the reduction in adduct level was higher
among younger subjects). Despite the statis-
tical signiﬁcance of the associations with age,
because the intercepts were large and the
coefﬁcients were very small, it is difﬁcult to
make any concrete inferences about the
effects of age on adduct levels and its tempo-
ral variability. However, if the observed
reduction in adduct levels was at least partly
due to modification in their dietary behav-
ior, then this ﬁnding, if real, would reﬂect a
trend that younger subjects were more likely
to change their diets after participating in
the cancer screening project.
The temporal variability in adduct levels
between two time points was inversely related
to the duration of time interval between time
points (i.e., the reduction in adduct levels
was higher among subjects for whom the
time interval between two blood draws was
shorter). The reasons for and implications of
this ﬁnding are not clear. The intraindividual
variability was higher among subjects with a
higher baseline adduct level. This finding
may indicate that subjects who had a higher
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Table 1. AFB1–albumin adduct levels at two time points by age, HBsAg status, anti-HCV status, GSTM1/T1
genotype, geographic area, and season.
Time 1 Time 2
Mean (median) Mean (median)
No. (pmol/mg) SD No. (pmol/mg) SD
All subjects 264 33.8 (22.1) 42.9  264 18.5 (14.3) 22.8
Age at time 1 (quartiles)
Q1 (30.3 to < 36.4) 66 28.5 (17.6) 37.4 66 14.6 (8.7) 13.4
Q2 (36.4 to < 41.3) 66 29.6 (20.7) 39.3 66 15.5 (12.8) 13.0
Q3 (41.3 to < 55.6) 66 41.3 (25.1) 58.5 66 22.5 (16.0) 32.3
Q4 (55.6 to 64.8) 66 35.8 (24.3) 31.5 66 21.7 (17.9) 25.5
Time interval between assays (quartiles)
Q1 (1.00 to < 1.18) 74 34.2 (21.0) 48.2 74 11.7 (5.0) 9.0
Q2 (1.18 to < 1.34) 64 36.9 (22.2) 50.7 64 25.7 (18.1) 31.2
Q3 (1.34 to < 2.00) 63 26.9 (21.2) 20.3 63 22.0 (17.9) 30.1
Q4 (2.00 to 3.17) 65 37.6 (24.4) 44.7 65 17.7 (14.7) 13.1
HBsAg status
Negative 132 35.3 (21.2) 50.4 132 17.2 (12.8) 21.7
Positive 132 32.3 (22.2) 34.1 132 19.9 (15.1) 23.7
GSTM1 genotype
Null 135 35.2 (21.0) 52.6 135 18.3 (14.6) 20.0
Non-null 87 36.4 (25.4) 33.4 87 20.9 (14.3) 29.7
Unknown 42 23.8 (22.3) 17.7 42 14.3 (13.9) 10.9
GSTT1 genotype
Null 131 34.5 (22.2) 36.9 131 17.7 (14.8) 14.2
Non-null 91 37.5 (21.2) 56.7 91 21.9 (13.8) 33.8
Unknown 42 23.6 (22.3) 17.8 42 13.7 (13.4) 10.7
Township 
Hu-Hsi 90 38.6 (23.9) 48.3 90 23.7 (18.1) 28.0
Ma-Kung 148 31.5 (20.3) 42.4 148 14.0 (7.5) 13.9
Pai-Hsa 26 30.3 (23.3) 20.2 26 26.3 (18.6) 35.1
Anti-HCV status
Negative 221 34.2 (22.1) 44.2 221 17.8 (14.0) 20.6
Positive 43 31.7 (22.6) 36.2 43 22.3 (17.9) 31.5
Season of blood draw
March–May 133 30.4 (21.2) 33.5 88 20.0 (14.9) 23.0
June–August 42 44.1 (28.7) 42.8 59 13.5 (14.1) 8.5
September–November 56 42.1 (21.0) 66.1 51 16.1 (10.7) 22.6
December–February 33 20.6 (22.1) 13.1 66 22.9 (15.2) 29.6
Same Season
No 171 32.6 (21.2) 42.8 171 19.5 (15.0) 23.6
Yes 93 36.1 (24.3) 43.4 93 16.9 (13.8) 21.1initial adduct level were more likely to
change their dietary patterns.
The temporal variability in adduct levels
differed with respect to geographic residence
of study subjects. The highest variability was
observed among subjects of Ma-Kung as
compared to those in Hu-Hsi and Pai-Hsa,
although the baseline adduct levels were sim-
ilar across all areas. These analyses were
adjusted for seasonal variability (as well as
other risk factors) in blood draws, hence any
differential seasonal effects (or effects of
other factors) across geographic areas are
unlikely to have any impact on this result.
This finding may reflect that residents of
Ma-Kung were more likely to have modiﬁed
their dietary pattern than subjects residing in
the other two areas. Ma-Kung is more urban
than the other two areas.
The study did not ﬁnd any effect of sea-
sonal variations on either the baseline or the
intraindividual variability in the AFB1–albu-
min adduct levels. The finding was similar
whether the seasons were deﬁned as narrow
as four seasons a year (3 months each) or as
broad as two seasons a year (6 months each).
Wang et al. (7), in their study in China,
observed different temporal trends in
AFB1–albumin adduct levels in two different
time periods. The ﬁndings of that study with
regard to seasonal variability in adduct levels
are not directly comparable to the current
study since Wang et al. (7) measured adduct
levels multiple times within a short period
(i.e., 12 weeks) at two different waves within
a year, and the current study measured
adduct levels at two different time points
with 1–3 years between blood draws.
Although not statistically signiﬁcant, the
intraindividual variability in the adduct levels
appeared to be higher among subjects who
were seronegative for HBsAg (i.e., the reduc-
tion in the adduct level was more pronounced
among subjects who were seronegative for
HBsAg). This ﬁnding was surprising, as the
subjects who tested seropositive for HBsAg
would have been expected to be more likely
to have altered their dietary habits. An alter-
native explanation for the finding could be
that, although the study subjects were appar-
ently healthy at the time of enrollment, it is
possible that subjects who were seropositive
for HBsAg had subclinical impaired liver
function and thus could have a defective
AFB1–albumin adduct metabolism. The
study by Wang et al. (7) found that HBsAg
status was not correlated to the temporal vari-
ability of AFB1–albumin adduct level.
One previous study found a higher vari-
ability of polycyclic aromatic hydrocarbon–
DNA adducts among subjects who carried
null genotypes for the GSTM1 gene (16).
The present study was the first to examine
the effect of GSTT1 and GSTM1 genotype
and anti-HCV status on the intraindividual
variability of the AFB1–albumin adduct lev-
els. We did not ﬁnd the GSTM1 or GSTT1
genotype status or anti-HCV status to have
any impact either on the baseline or on the
temporal variability of the AFB1–albumin
adduct levels. Wild et al. (15) recently pub-
lished a study showing no association
between AFB1–albumin adduct levels and
GSTT1 genotype in a Gambian population,
but the authors found higher adduct levels
among non–HBV-infected subjects with the
GSTM1 null genotype.
Several limitations of the current study
should be borne in mind while interpreting
the findings. First, we examined aflatoxin–
albumin adducts at only two time points
with an interval of 1–3 years, limiting the
capability to examine the temporal trends
over a shorter duration. Second, although
dietary data (as sources of aﬂatoxin exposure)
were collected at the time of recruitment
(i.e., at time 1) on each subject as part of the
structured interview, data on the changes of
dietary and nondietary exposure at the time
of second blood draw (i.e., at time 2) were
not collected. The lack of sufﬁcient dietary
and nondietary data on aﬂatoxin exposure at
time 2 limits our ability to directly correlate
the observed temporal trends in adduct levels
with changes to specific dietary and/or
nondietary sources from the present data.
However, questionnaire-based dietary infor-
mation is of limited utility in determining
individual exposure to aflatoxin. For exam-
ple, a nested study carried out in Shanghai
that found an association between afla-
toxin–albumin adducts and HCC found no
association with dietary aﬂatoxin consump-
tion based on in-person food frequency
interview combined with the survey of mar-
ket foods in the study region (17). In 1988,
a study of 42 residents of Guangxi Province
in China established that albumin adducts
were a valid marker of aﬂatoxin exposure by
comparing adduct levels to the levels of aﬂa-
toxin in portions of the food consumed (18). 
A third limitation of the present study is
that the study participants were recruited
from three different townships where the
distribution of sources of aﬂatoxin as well as
their changes over time may not have been
homogenous. Although inclusion of town-
ship variables in the multivariate model
adjusted the impact of results in relation to
other covariates, the interpretation of the
observed relationship between township
itself and temporal variability in adducts is
somewhat complicated by the lack of data
on the distribution and changes in sources of
aﬂatoxin within individual townships. 
In conclusion, we found that AFB1–albu-
min adduct levels varied over time among
apparently healthy individuals residing in
three townships of Taiwan. This temporal
intraindividual variability in adduct levels
was higher among younger subjects and sub-
jects with an initial high adduct level. HBsAg
or anti-HCV infection and GSTM1 or
GSTT1 genotype status did not have any sig-
nificant effects on the intraindividual vari-
ability of AFB1–albumin adduct levels.
Dietary modiﬁcation appears to be an impor-
tant determinant of aﬂatoxin exposure reduc-
tion in Taiwan.
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Table 2. Effect of different environmental and genetic factors on the AFB1–albumin adduct level and its
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